Recent studies have demonstrated that assessment of high-density lipoprotein (HDL) functionality indices, instead of HDL cholesterol measurement, is a more robust tool for the evaluation of the functional status of HDL and cardiovascular risk. There are qualitative abnormalities of HDL particles in familial hypercholesterolemia (FH) patients that might represent potential therapeutic targets. Despite the potential promise of optimizing HDL functionality for the treatment of FH, there has been no prior comprehensive review focusing on the impact of different lipid-modifying therapies on HDL functionality in FH patients. In the present review, we aim to fulfill this gap and provide a concise summary on the impact of different lipid-modifying therapies on HDL functionality in FH.

最近的研究表明，高密度脂蛋白（HDL）功能指数的评估而不是HDL胆固醇的测量，是评估HDL功能状态和心血管风险的更强大的工具。家族性高胆固醇血症（FH）患者的HDL颗粒存在质的异常，可能代表潜在的治疗靶点。尽管有可能优化HDL功能来治疗FH，但之前尚未有针对FH患者不同脂质修饰疗法对HDL功能的影响的全面综述。在本综述中，我们旨在弥补这一空白，并简要概述不同脂质修饰疗法对FH中HDL功能的影响。